Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment
Authors
Keywords
Inclisiran, Hepatic impairment, Hyperlipidemia, Pharmacodynamics, Pharmacokinetics
Journal
Journal of Clinical Lipidology
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-01-10
DOI
10.1016/j.jacl.2022.01.001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
- (2021) R. Scott Wright et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review
- (2020) Eric Bruckert et al. ADVANCES IN THERAPY
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Call to Action: Urgent Challenges in Cardiovascular Disease: A Presidential Advisory From the American Heart Association
- (2019) Mark McClellan et al. CIRCULATION
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
- (2019) Kausik K. Ray et al. JAMA Cardiology
- Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9
- (2019) Charles A. German et al. BIODRUGS
- Inclisiran—New hope in the management of lipid disorders?
- (2019) Krzysztof Dyrbuś et al. Journal of Clinical Lipidology
- Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
- (2019) R. Scott Wright et al. MAYO CLINIC PROCEEDINGS
- Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression
- (2018) Jennifer L.S. Willoughby et al. MOLECULAR THERAPY
- Reprint of: Impact of Lipids on Cardiovascular Health
- (2018) Brian A. Ference et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2018) Gregory A Roth et al. LANCET
- Inhibiting PCSK9 — biology beyond LDL control
- (2018) Robert M. Stoekenbroek et al. Nature Reviews Endocrinology
- Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs
- (2017) Anastasia Khvorova NEW ENGLAND JOURNAL OF MEDICINE
- Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease
- (2017) Christopher P. Cannon et al. JAMA Cardiology
- Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment
- (2016) John P. Gibbs et al. JOURNAL OF CLINICAL PHARMACOLOGY
- National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report
- (2015) Terry A. Jacobson et al. Journal of Clinical Lipidology
- An assessment by the Statin Liver Safety Task Force: 2014 update
- (2014) Harold Bays et al. Journal of Clinical Lipidology
- Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
- (2013) Daniel Urban et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Long-Term Survival and Recurrence After Acute Myocardial Infarction in England, 2004 to 2010
- (2012) Kate Smolina et al.
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search